Optical Biopsy for Distal Margin in Low Rectal Cancer

Sponsor
Nanfang Hospital of Southern Medical University (Other)
Overall Status
Unknown status
CT.gov ID
NCT04016948
Collaborator
Southern Medical University, China (Other), Shenzhen Hospital of Southern Medical University (Other)
146
1
2
46.1
3.2

Study Details

Study Description

Brief Summary

This is a multi-center prospective randomized controlled study. In this study, the investigators will use confocal laser endomicroscopy to make real-time in vivo optical biopsy of distal margin in rectal cancer surgery and help surgeons to make surgical decision.The investigators also assess the accuracy of CLE optical biopsy, compared with intra-operative frozen section.

Condition or Disease Intervention/Treatment Phase
  • Device: Probe-based confocal laser endomicroscopy optical biopsy
  • Device: Intra-operative frozen section
N/A

Detailed Description

In low rectal cancer surgery, how to select the precise dissection plane and optimal surgical procedure is an important challenge for surgeons. In current clinic, surgeons select dissection plane by a comprehensive judgment of pre-operative pelvis MRI, colonoscopy and digital rectal examination, then through submitting the "doughnut" after cutting and anastomosis to intra-operative frozen section (IFS) to definite whether there is residual tumor in distal margin (DM). However, IFS can only make diagnosis using the tissue specimen in vitro and time-consuming. Once the IFS confirm positive margin, it always means anal resection should be implemented to ensure radical treatment. Therefore, if there is a real-time in situ examination method to evaluate DM in vivo, it will bring great benefits to both surgeons and patients.

Confocal laser endomicroscopy (CLE) had been widely used in medical field to diagnose colorectal disease, but it is seldom applied in surgical filed especially in rectal cancer to make optical biopsy and help surgical decision-making. Therefore, the investigators hypothesize that CLE can real-time in situ evaluate DM during surgery in rectal cancer and its accuracy is non-inferior to intra-operative frozen section.

In this study, the investigators will randomly assign patients to the experimental group (CLE optical biopsy) and control group (IFS). Using H-E staining pathological diagnosis as golden standard, the accuracy, sensitivity and specificity of both CLE optical biopsy and IFS will be evaluated and compared. And the investigators will also evaluate patients' postoperative urinary function, defection function and quality of life through a year follow-up.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
146 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
A Multicenter Randomized Study of Real-time In-vivo Confocal Laser Endomicroscopy Optical Biopsy for Distal Margin in Low Rectal Cancer Compared to Intraoperative Frozen Section
Actual Study Start Date :
Jun 28, 2017
Anticipated Primary Completion Date :
Sep 1, 2020
Anticipated Study Completion Date :
May 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Probe-based confocal laser endomicroscopy(pCLE)

Confocal laser endomicroscopy optical biopsy will be performed in surgery for patients assigned to this group

Device: Probe-based confocal laser endomicroscopy optical biopsy
In the pCLE group, after intravenous injection of fluorescein, the optical biopsy will be performed, using a confocal miniprobe, to exam the rectal mucosa when the rectum transection is ready. The raters will analyse the CLE images to determine whether the distal margin is positive. In the IFS group, intra-operative frozen section will be performed at the site of distal margin after the rectum transection.

Active Comparator: Intra-operative frozen section(IFS)

Intra-operative frozen section will be performed for patients assigned to this group

Device: Intra-operative frozen section
In the pCLE group, after intravenous injection of fluorescein, the optical biopsy will be performed, using a confocal miniprobe, to exam the rectal mucosa when the rectum transection is ready. The raters will analyse the CLE images to determine whether the distal margin is positive. In the IFS group, intra-operative frozen section will be performed at the site of distal margin after the rectum transection.

Outcome Measures

Primary Outcome Measures

  1. Accuracy of optical biopsy [One week after surgery]

    Accuracy of confocal laser endomicroscopy optical biopsy of distal margin is determined by the pathology result.

Secondary Outcome Measures

  1. Sensitivity and Specificity [One week after surgery]

    Sensitivity and specificity of confocal laser endomicroscopy optical biopsy of distal margin are determined by the pathology result.

  2. Operation related indexes [One week after surgery]

    Operation time in minutes

  3. Postoperative function recovery [Up to 12 months]

    Defecation and sphincter function will be combined to report Wexner score.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Ages from 18 to 70 years.

  • Rectal tumor confirmed pathologically by endoscopic biopsy.

  • The distance from lower edge of tumor to the dentate line is less than 5cm.

  • Plan to perform curative resection.

  • ASA(American Society of Anesthesiology)score class I,II,or III.

  • Able to provide written informed consent.

Exclusion Criteria:
  • Intestinal perforation or acute intestinal obstruction.

  • Multiple distant metastasis and can not R0 resection.

  • T4b according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual Seventh Edition.

  • Pregnancy or breastfeeding.

  • Impaired renal function

  • American Society of Anesthesiology score (ASA) class IV or V.

  • Unable or refuse to provide written informed consent.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Nanfang Hospital, Southern Medical University Guangzhou Guangdong China 510-515

Sponsors and Collaborators

  • Nanfang Hospital of Southern Medical University
  • Southern Medical University, China
  • Shenzhen Hospital of Southern Medical University

Investigators

  • Principal Investigator: Jun Yan, M.D., Ph.D, Nanfang Hospital of Southern Medical University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Nanfang Hospital of Southern Medical University
ClinicalTrials.gov Identifier:
NCT04016948
Other Study ID Numbers:
  • yanjun
First Posted:
Jul 12, 2019
Last Update Posted:
Jul 12, 2019
Last Verified:
Jul 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Nanfang Hospital of Southern Medical University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 12, 2019